Evidence map›Paper›PMID 25807502›Full record

ArticlePloS one2015

APOBEC3A is implicated in a novel class of G-to-A mRNA editing in WT1 transcripts.

Ahmadreza Niavarani, Erin Currie, Yasmin Reyal, Fernando Anjos-Afonso, Stuart Horswell, Emmanuel Griessinger, Jose Luis Sardina, Dominique Bonnet

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Ahmadreza NiavaraniHaematopoietic Stem Cell Laboratory, Cancer Research UK, London Research Institute, London, United Kingdom; Digestive Disease Research Institute (DDRI), Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Erin CurrieHaematopoietic Stem Cell Laboratory, Cancer Research UK, London Research Institute, London, United Kingdom.
Yasmin ReyalDepartment of Haematology, University College London Hospitals NHS Trust, London, United Kingdom.
Fernando Anjos-AfonsoHaematopoietic Stem Cell Laboratory, Cancer Research UK, London Research Institute, London, United Kingdom.
Stuart HorswellDepartment of Bioinformatics, Cancer Research UK, London Research Institute, London, United Kingdom.
Emmanuel GriessingerINSERM U1065, Mediterranean Centre for Molecular Medicine (C3M), Université Nice Sophia Antipolis, Nice, France.
Jose Luis SardinaInstituto de Biología Funcional y Genómica, CSIC/Universidad de Salamanca, Salamanca, Spain.
Dominique BonnetHaematopoietic Stem Cell Laboratory, Cancer Research UK, London Research Institute, London, United Kingdom.
Cancer Research UK · GBInserm · FRTehran University of Medical Sciences · IRUniversidad de Salamanca · ESUniversity College London · GB

Funding

Cancer Research UK
6 · The paper itself

Abstract

Classic deamination mRNA changes, including cytidine to uridine (C-to-U) and adenosine to inosine (A-to-I), are important exceptions to the central dogma and lead to significant alterations in gene transcripts and products. Although there are a few reports of non-classic mRNA alterations, as yet there is no molecular explanation for these alternative changes. Wilms Tumor 1 (WT1) mutations and variants are implicated in several diseases, including Wilms tumor and acute myeloid leukemia (AML). We observed two alternative G-to-A changes, namely c.1303G>A and c.1586G>A in cDNA clones and found them to be recurrent in a series of 21 umbilical cord blood mononuclear cell (CBMC) samples studied. Two less conserved U-to-C changes were also observed. These alternative changes were found to be significantly higher in non-progenitor as compared to progenitor CBMCs, while they were found to be absent in a series of AML samples studied, indicating they are targeted, cell type-specific mRNA editing modifications. Since APOBEC/ADAR family members are implicated in RNA/DNA editing, we screened them by RNA-interference (RNAi) for WT1-mRNA changes and observed near complete reversal of WT1 c.1303G>A alteration upon APOBEC3A (A3A) knockdown. The role of A3A in mediating this change was confirmed by A3A overexpression in Fujioka cells, which led to a significant increase in WT1 c.1303G>A mRNA editing. Non-progenitor CBMCs showed correspondingly higher levels of A3A-mRNA and protein as compared to the progenitor ones. To our knowledge, this is the first report of mRNA modifying activity for an APOBEC3 protein and implicates A3A in a novel G-to-A form of editing. These findings open the way to further investigations into the mechanisms of other potential mRNA changes, which will help to redefine the RNA editing paradigm in both health and disease.

Indexed as

RNA EditingAdenosineBase SequenceCytidine DeaminaseGuanineHumansLeukemia, Myeloid, AcuteLeukocytes, MononuclearMolecular Sequence DataMutationProteinsRNA InterferenceRNA, MessengerRNA, Small InterferingSequence Analysis, DNAUmbilical CordAdenosineAPOBEC3A protein, humanCytidine DeaminaseGuanineProteinsRNA, MessengerRNA, Small InterferingWT1 protein, humanWT1 Proteins

Identifiers

PMID25807502
PMCPMC4373805
OpenAlexW2116087493

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.